Daily pill shows promise for diabetes control in real life

NCT ID NCT05443568

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in everyday medical practice in Israel. Researchers tracked changes in blood sugar and body weight over about 8-10 months. The goal was to see if the pill helps lower blood sugar levels in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Rybelsus)
What this could lead to: If successful, this study could confirm that oral semaglutide helps manage blood sugar and weight in real-world settings, supporting its use for type 2 diabetes.
What could go wrong: This is an observational study with no control group, so results may not prove cause and effect. It is also completed and not testing a new treatment, so no breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Master Centre for Israel

Kfar Saba, 44425, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.